Treatment for Non-Alcoholic Fatty Liver With Different Doses of Vitamin E
NCT01792115 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 22
Last updated 2020-11-04
Summary
Background:
* Non-alcoholic fatty liver disease (NAFLD) is an excess accumulation of fat in the liver cells. It is associated with obesity, high blood pressure, high cholesterol, and diabetes. Some people with NAFLD only have excess fat in the liver. However, other people may develop a worse form of NAFLD with liver injury and scarring. This form, called non-alcoholic steatohepatitis (NASH), can lead to liver failure, liver cancer, and death. Not much is known about why some people develop NASH and others do not.
* Lifestyle changes such as diet, exercise, and weight loss can decrease the liver damage in NAFLD. Some studies show that vitamin E can also help treat NAFLD. The dose of vitamin E used in these studies is almost 40 times the recommended amount of vitamin E intake from food. It is unclear whether a lower dose could achieve the same effect. Researchers also want to study how vitamin E works at different doses to treat NAFLD.
Objectives:
* To find out the most effective dose of vitamin E to treat NAFLD.
* To gain a better understanding of how NAFLD and NASH develop, and predict who will respond to treatment.
Eligibility:
\- Individuals at least 18 years of age with suggestion of non-alcoholic fatty liver disease.
Design:
* Participants will be screened with a physical exam and medical history. Blood and urine samples will be collected.
* For the first 12 weeks of the study, participants will meet with a nutritionist. They will have personalized diet and exercise plans. Treatment will be monitored with diaries and questionnaires to fill out at home. Participants will also wear a pedometer to measure physical activity.
* After the 12-week period, participants will have a full physical examination with the following tests:
* Blood tests
* Glucose tolerance tests
* Imaging studies (DEXA scan and magnetic resonance imaging)
* Liver and fatty tissue biopsy
* Two weeks after the tests, participants will start vitamin E treatment. They will take up to two pills a day, taken with fat-containing foods.
* 4 weeks after starting treatment they will have a repeat full evaluation with imaging tests, blood work, and liver and fat biopsies.
* Participants who are taking vitamin E will take it for up to 120 weeks. They will have monitoring visits every 8 to 12 weeks. At the end of 120 weeks, they will have another full evaluation, with imaging tests, blood work, and liver and fat biopsies.
Conditions
Interventions
- DRUG
-
Vitamin E 200 IU/d
Supplement-low dose
- DRUG
-
Vitamin E 400 IU/d
Supplement-intermediate dose
- DRUG
-
Vitamin E 800 IU/d
Supplement High Dose
- BEHAVIORAL
-
Diet and Exercise
Diet and Exercise for all Arms of the study at baseline
Sponsors & Collaborators
-
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
lead NIH
Principal Investigators
-
Yaron Rotman, M.D. · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Study Design
- Allocation
- RANDOMIZED
- Purpose
- BASIC_SCIENCE
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2013-05-01
- Primary Completion
- 2019-08-30
- Completion
- 2019-08-30
- FDA Drug
- Yes
Countries
- United States
Study Locations
More Related Trials
-
Comparing the Effects of Vitamin E, Ursodeoxycholic Acid and Pentoxyfylline on Egyptian Non-alcoholic Steatohepatitis (NASH) Patients
NCT04977661 ·Status: COMPLETED ·Phase: PHASE4
-
Effect of Multi Vitamin and Mineral Supplementation of Liver Enzymes and Sonography in Patient With NAFLD
NCT05897606 ·Status: COMPLETED ·Phase: PHASE1
-
Pioglitazone vs Vitamin E vs Placebo for Treatment of Non-Diabetic Patients With Nonalcoholic Steatohepatitis (PIVENS)
NCT00063622 ·Status: COMPLETED ·Phase: PHASE3
-
Stimulating Fat Tissue Storage With Niacin to Reduce Fat Accumulation in the Liver.
NCT06843148 ·Status: RECRUITING ·Phase: NA
-
Study on the Correlation Between Fat Soluble Vitamins and Non-alcoholic Fatty Liver Disease
NCT06512701 ·Status: RECRUITING
-
Effect of Spironolactone and Vitamin E in Patients With Nonalcoholic Fatty Liver Disease
NCT01147523 ·Status: COMPLETED ·Phase: PHASE2
-
Vitamin E Versus Placebo for the Treatment of Non Diabetic Patients With Nonalcoholic Steatohepatitis
NCT02962297 ·Status: COMPLETED ·Phase: NA
-
Effect of Vitamin A and Calcium in Patients With Non-alcoholic Fatty Liver Disease
NCT06031532 ·Status: COMPLETED
-
Effect of Vitamin E on Pediatric Nonalcoholic Fatty Liver Disease (NAFLD)
NCT00655018 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Interventional Strategy in Tackling Emerging Non-alcoholic Fatty Liver Disease in Childhood Obesity
NCT05905185 ·Status: COMPLETED ·Phase: PHASE4
-
Polyunsaturated Fatty Acids in Patients With NAFLD.
NCT02647294 ·Status: COMPLETED ·Phase: NA
-
Zinc Supplementation in Alcoholic Cirrhosis
NCT02072746 ·Status: COMPLETED ·Phase: NA
-
A Carbohydrate-restricted Diet to Reverse Fatty Liver in Adolescents With Obesity
NCT02787668 ·Status: COMPLETED ·Phase: NA
-
DHA and Vitamin D in Children With Biopsy-proven NAFLD
NCT02098317 ·Status: COMPLETED ·Phase: PHASE3
-
Effects of Carnitine Supplementation on Liver and Muscle
NCT03439917 ·Status: COMPLETED ·Phase: NA
-
Efficacy and Tolerance of Treatment With DHA, Choline and Vitamin E in Children With Non-alcoholic Steatohepatitis
NCT01934777 ·Status: COMPLETED ·Phase: PHASE3
-
Vitamin Replacement in Abetalipoproteinemia
NCT00004574 ·Status: COMPLETED
-
Fatty Liver Disease in Obese Children
NCT02117700 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Efficacy of Phosphatidylcholine in NAFLD
NCT04411862 ·Status: COMPLETED ·Phase: PHASE3
-
Effect of Alpha Lipoic Acid on Non-alcoholic Fatty Liver Diseases
NCT04475276 ·Status: COMPLETED ·Phase: PHASE4
-
Impact of Fructose Consumption on Intestinal Permeability in Non-alcoholic Fatty Liver Disease (NAFLD) - a Pilot Study.
NCT01696487 ·Status: COMPLETED ·Phase: NA
-
Fish Oil and Diet for the Treatment of Non-Alcoholic Steatohepatitis (NASH)
NCT00845845 ·Status: TERMINATED ·Phase: PHASE2
-
A Feasibility Trial of OCM Supplements for the Treatment of NAFLD
NCT05720702 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Role of Vitagliptin and Vitamin D in the Treatment of Non Alcoholic Fatty Liver Disease (NAFLD)
NCT01083992 ·Status: UNKNOWN ·Phase: NA
-
Hydroxytyrosol and Vitamin E in Pediatric NASH
NCT02842567 ·Status: COMPLETED ·Phase: PHASE3